Drug intelligence / Profile preview

CD200AR-L + GBM6-AD

Development stage: Unknown
Lead developer: OX2 Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intradermal, Topical

Overview

CD200AR-L + GBM6-AD is a novel immunotherapy combination consisting of CD200AR-L (a CD200 activation receptor ligand) and GBM6-AD (an allogeneic tumor lysate vaccine). CD200AR-L binds to the CD200 activation receptor on immune cells, activating them and overcoming inhibitory signals caused by CD200 protein secreted by tumor cells. GBM6-AD is a tumor lysate vaccine. This combination is being developed to treat malignant gliomas, particularly in children and young adults with recurrent High Grade Glioma (HGG) or newly diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).

Targets

CD200R1L (CD200 receptor 1-like)

Beyond the preview

Go deeper on CD200AR-L + GBM6-AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD200AR-L + GBM6-AD.

Explore the full profile